Inhalation Sciences Sweden AB (ISAB), a pioneering medtech company specializing in aerosol technology, has today announced the receipt of a substantial order for its Inhalation Research Service (IRS) from a top-ranked European university hospital. The order involves the deployment of ISAB’s flagship PreciseInhale® in vivo platform, which is recognized globally for its cutting-edge capabilities in accurately delivering and characterizing airborne drug particles for respiratory research.

This new collaboration comes at a pivotal moment for respiratory care and pulmonary research, as hospitals across Europe intensify their focus on evaluating innovative therapies and delivery mechanisms for both chronic and acute respiratory diseases. The PreciseInhale® platform enables highly standardized inhalation studies by precisely controlling particle size, dose, and exposure conditions, making it a critical asset for translational and clinical research. Hospitals adopting IRS benefit from state-of-the-art imaging, patient monitoring, and data analytics integrated directly into workflows, all powered by ISAB’s proprietary technology suite.

The university hospital’s order addresses several strategic priorities: expanding capacity for preclinical assessments, supporting the rapid evaluation of new pharmaceutical aerosols, and strengthening interdisciplinary partnerships across pulmonary medicine, diagnostics, and critical care departments. By integrating PreciseInhale®, facility managers and clinical leadership can accelerate lab-to-bedside translation for novel inhaled treatments, including antibodies, gene therapies, and complex biologic formulations targeting conditions such as COPD, asthma, and ARDS.

From a facilities management perspective, the IRS contract will streamline laboratory operations, bolster quality assurance, and help meet regulatory compliance for inhalation studies, especially as EU and local agencies enforce more stringent controls related to aerosol medicine safety and efficacy. Hospital administrators will gain access to detailed metrics supporting procurement decisions, asset utilization, and ROI modeling relative to other inhalation technology investments.

This partnership also strengthens the hospital’s infrastructure for patient-centric innovation, reflecting a broader trend in European healthcare toward digitization and interconnected research platforms. Procurement professionals will benefit from ISAB’s scalable solution, which seamlessly integrates with existing digital infrastructure—enabling rapid adoption without extensive systems overhaul. The integration of PreciseInhale® is expected to support ongoing staff training, workflow optimization, and expansion of research capability, enhancing the hospital’s reputation as a center of excellence in respiratory care.

ISAB’s market leadership in precision aerosol technology has been further solidified by this contract, reflecting growing demand from academic medical centers and leading clinical research hubs throughout Europe. The firm’s CEO commented on the order: “This contract demonstrates strong confidence in our IRS and PreciseInhale® solution, enabling our partner hospitals to deliver advanced respiratory science—from early-stage research through to patient care. The unique features of our platform are increasingly seen as best-practice standards in translational pulmonary medicine.”

Clinical teams at the university hospital will now harness ISAB’s analytical tools—real-time data monitoring, nuanced particle characterization, and harmonized reporting—which are essential for developing next-generation respiratory therapies. These capabilities support collaborative projects between respiratory physicians, laboratory managers, and pharmaceutical partners, fostering innovation at every stage of the care pathway.

For healthcare technology suppliers, the partnership serves as a blueprint for integrating smart research services and MedTech innovations with hospital operations, further driving digital transformation and evidence-based practice. Facility managers and clinical leadership are poised to realize enhanced research productivity, improved standardization, and increased agility in pursuing breakthrough treatments for Europe’s most pressing respiratory health challenges.

The contract underscores a wider European movement prioritizing business-relevant solutions that directly empower healthcare organizations to advance patient care, streamline operations, and maintain competitive advantage in an evolving medtech landscape. As the IRS project moves forward, stakeholders anticipate meaningful improvements in research quality, regulatory readiness, and strategic outcomes for both hospital and industry partners.